Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement
Reported Earlier, NeuroSense Therapeutics Prices $4.5M Registered Direct Offering Of 2.98M Shares And Concurrent Private Placement
NeuroSense Therapeutics Ltd, a company developing novel treatments for severe neurodegenerative diseases, today announced it has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 2,980,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent private placement at a combined purchase price of $1.50 per ordinary share.
开发严重神经退行性疾病新疗法的公司NeuroSense Therapeutics Ltd今天宣布，它已与一家专注于医疗保健的单一机构投资者签订证券购买协议，通过注册直接发行购买和出售298万股普通股，并发普通认股权证，以每股普通股1.50美元的合并收购价购买最多298万股普通股。
The ordinary warrants issued pursuant to the concurrent private placement will have an exercise price of $1.50 per ordinary share, will be immediately exercisable and will expire 5 years from the initial exercise date.
根据并行私募发行的普通认股权证的行使价为每股普通股1.50美元，可立即行使，并将自首次行使之日起5年后到期。